Mar 17, 2021

"Fastest growing" RPM platform 100Plus raises $25m

patient monitoring
elderly care
Leila Hawkins
2 min
"Fastest growing" RPM platform 100Plus raises $25m
100Plus announces funding to increase adoption of its remote patient monitoring platform...

Remote patient monitoring platform 100Plus this week announced it had received $25m funding to grow and increase patient engagement. The US company says they are "the fastest growing remote patient platform for doctors and their patients". We take a closer look at what they offer. 

Launched in 2019, 100Plus helps clinicians monitor their elderly and chronic disease patients remotely, with the aim of proactively engaging patients so they can avoid expensive, episodic care. Its Virtual Medical Assistant reaches out to patients daily to ensure they are testing regularly and that their tests are in a safe range; if not clinical staff are notified. 

Additionally the platform provides data to inform clinical decisions that lead to better care, and CEO Ryan Howard explains that it is unique by being the only solution of its kind to use AI. 

"100Plus is the only remote patient monitoring product to utilise artificial intelligence and offer an end-to-end solution, including patient outreach, device setup, patient engagement and automated billing" he says. 

Available to patients on Medicare plans at no extra cost, it is delivered fully configured, without the need to connect to a smartphone, app, Bluetooth or WiFi. Several devices are available including a blood pressure cuff, glucose monitor, pulse oximeter and digital thermometer. 

The company recently signed a distribution partnership with AdvancedMD, DrChrono and athenahealth, medical billing and electronic health record providers, which will enable 100Plus to reach more than 250,000 medical practitioners in the US.  

Over the next few years they plan to expand their device line to include additional monitoring devices. "We will also innovate on our AI solution developed to increase patient engagement" Howard says. 

"Using SMS, the platform sends personalised messages to drive patient involvement in the management of their health, including monitoring reminders, follow up care instructions and feedback on their remote monitoring numbers. Patients can interact and ask questions and receive tailored responses based on their treatment plan. When needed, the platform will triage messages that require immediate physician interaction." 

"Remote patient monitoring has more potential than any other initiative to dramatically decrease the healthcare costs associated with chronic conditions as well as help patients avoid episodic care" he adds. 

"With Medicare committed to reimbursing remote patient monitoring long-term, physicians now have both the incentives and with 100Plus a seamless end-to-end tool to improve care and potentially save the lives of millions of patients."

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article